The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy
Open accessAbstract
PURPOSE: Approximately 30%-40% of patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) infused with CD19-targeted chimeric antigen receptor (CAR) T cells achieve durable responses. Consensus guidelines suggest avoiding bendamustine before apheresis, but specific data in this setting are lacking. We report distinct outcomes after CAR T-cell therapy according to previous bendamustine exposure. METHODS: The study included CAR T-cell recipients from seven European sites. Safety, efficacy, and CAR T-cell expansion kinetics were analyzed according to preapheresis bendamustine exposure. Additional studies on the impact of the washout period and bendamustine dose were performed. Inverse probability treatment weighting (IPTW) and propensity score matching (PSM) analyses were carried out for all efficacy comparisons between bendamustine-exposed and bendamustine-naïve patients. RESULTS: The study included 439 patients with R/R LBCL infused with CD19-targeted commercial CAR T cells, of whom 80 had received bendamustine before apheresis. Exposed patients had significantly lower CD3 + cells and platelets at apheresis. These patients had a lower overall response rate (ORR, 53% v 72%; P < .01), a shorter progression-free survival (PFS, 3.1 v 6.2 months; P = .04), and overall survival (OS, 10.3 v 23.5 months; P = .01) in comparison with the bendamustine-naïve group. Following adjustment methods for baseline variables, these differences were mitigated. Focusing on the impact of bendamustine washout before apheresis, those with recent (<9 months) exposure (N = 42) displayed a lower ORR (40% v 72%; P < .01), shorter PFS (1.3 v 6.2 months; P < .01), and OS (4.6 v 23.5 months; P < .01) in comparison with bendamustine-naïve patients. These differences remained significant after IPTW and PSM analysis. Conversely, the cumulative dose of bendamustine before apheresis did not affect CAR-T efficacy outcomes. CONCLUSION: Recent bendamustine exposure before apheresis was associated with negative treatment outcomes after CD19-targeted CAR T-cell therapy and should be therefore avoided in CAR T-cell candidates.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“were higher for participants treated with epcoritamab plus R² due to overlapping toxicities in line with previous reports of T-cell engaging immunotherapies.”
In the citing paper
“early-phase trials consistently reported complete response rates of more than 65%. 29-33”
Citations
Cites
Austin, P. C. (2011) · Multivariate Behavioral Research · doi:10.1080/00273171.2011.568786 · Cited by 12,242 · cited 1×
“…balanced in terms of baseline variables, an inverse probability treatment weighting (IPTW) choosing the average treatment effect among the treated method to estimate weights was performed, taking into account both unbalanced and prognostically relevant variables 30,31 (Data Supplement, Table S3).”
MethodAxicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · cited 2×
“%] and tisa-cel in 185 [42”
BackgroundLocke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Crump, M., Neelapu, S. S., Farooq, U., Van Den Neste, E., Kuruvilla, J., Westin, J., Link, B. K., Hay, A., Cerhan, J. R., Zhu, L., et al. (2017) · Blood · doi:10.1182/blood-2017-03-769620 · Cited by 1,703
Rummel, M. J., Niederle, N., Maschmeyer, G., Banat, G. A., von Grünhagen, U., Losem, C., Kofahl-Krause, D., Heil, G., Welslau, M., Balser, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61763-2 · Cited by 1,510
Nastoupil, L. J., Jain, M. D., Feng, L., Spiegel, J. Y., Ghobadi, A., Lin, Y., Dahiya, S., Lunning, M., Lekakis, L., Reagan, P., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02104 · Cited by 801
Research works printed but not linked: 3
- Bethge WA, 2022, Blood, 140, 349
- Neelapu SS, 2023, Blood, 141, 2307
- van Buuren S, 2011, J Stat Softw, 45, 1
Cited by
Neelapu, S. S., Chávez, J. C., Sehgal, A. R., Epperla, N., Ulrickson, M. L., Bachy, E., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2023) · Blood · doi:10.1182/blood.2023021243 · Cited by 194
Rejeski, K., Jain, M. D., Shah, N. N., Perales, M., & Subklewe, M. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00077-2 · Cited by 153
Self-citationBispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas
Trabolsi, A., Arumov, A., & Schatz, J. H. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-00997-w · Cited by 137
Lin, Y., Qiu, L., Usmani, S. Z., Joo, C. W., Costa, L. J., Derman, B. A., Du, J., Einsele, H., de Larrea, C. F., Hájek, R., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00094-9 · Cited by 105
Costa, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 101
Brooks, T., Zabor, E. C., Bedelu, Y. B., Yang, X., Karimi, Y. H., Nedved, A. N., Wang, Y., Dave, N., Landsburg, D. J., Baron, M. K., et al. (2025) · Blood · doi:10.1182/blood.2025029117 · Cited by 60
Bock, A. M., & Epperla, N. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01702-5 · Cited by 54
Shumilov, E., Scholz, J. K., Seib, M., Mazzeo, P., Wurm‐Kuczera, R., Vučinić, V., Holtick, U., Boyadzhiev, H., Melchardt, T., Hölscher, A. S., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015719 · Cited by 51
Shumilov, E., Wurm‐Kuczera, R., Kerkhoff, A., Wang, M., Melchardt, T., Holtick, U., Bacher, U., Staber, P. B., Mazzeo, P., Leng, C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014903 · Cited by 48
Self-citationMajor, A., Yu, J., Shukla, N., Che, Y., Karrison, T. G., Treitman, R., Kamdar, M. K., Haverkos, B. M., Godfrey, J. K., Babcook, M. A., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010016 · Cited by 48
Herzberg, C., Schiele, P., Walter, A. L., Hamm, F., Obermayer, B., Kath, J., Busch, D., Stroux, A., Frick, M., Penack, O., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010709 · Cited by 45
Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I., Gabrielli, G., Nasta, S. D., Porazzi, P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011492 · Cited by 44
Haydu, J. E., & Abramson, J. S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2021004535 · Cited by 42
Falchi, L., Nijland, M., Huang, H., Linton, K. M., Seymour, J. F., Tao, R., Kwiatek, M., Costa, A., Vassilakopoulos, T. P., Greil, R., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02360-8 · Cited by 41
Saldarriaga, M. M., Pan, D., Unkenholz, C., Mouhieddine, T. H., Velez-Hernandez, J. E., Engles, K., Fein, J. A., Monge, J., Rosenbaum, C. A., Pearse, R. N., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012470 · Cited by 40
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Liang, E. C., Albittar, A. A., Huang, J. J., Hirayama, A. V. V., Kimble, E. L., Portuguese, A. J., Chapuis, A. G., Shadman, M. S., Till, B. G., Cassaday, R. D., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011399 · Cited by 40
Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma
Medina-Olivares, F. J., León, A. G., & Ghosh, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1397613 · Cited by 39
Exosomes in review: A new frontier in CAR-T cell therapies
Wang, J. S., Schellenberg, S., Demeros, A., & Lin, A. Y. (2025) · Neoplasia · doi:10.1016/j.neo.2025.101147 · Cited by 38
Stock, S., Bücklein, V., Blumenberg, V., Magno, G., Emhardt, A., Holzem, A. M. E., dos Santos, D. M. C., Schmidt, C., Grießhammer, S., Frölich, L., et al. (2025) · HemaSphere · doi:10.1002/hem3.70062 · Cited by 36
Self-citationTreatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options
Martín, A., Cabero, A., & Gutierrez, N. C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010070 · Cited by 34
Dulobdas, V., Kirkwood, A. A., Serpenti, F., Gautama, B., Panopoulou, A., Mathew, A., Gabriel, S., Malladi, R. K., Pealing, J., Bonney, D. K., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01225-9 · Cited by 33
Self-citationSequencing of Anti-CD19 Therapies in the Management of Diffuse Large B-Cell Lymphoma
Lownik, J. C., Boiarsky, J., Birhiray, R. E., Merchant, A. A., & Mead, M. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1962 · Cited by 27
Sequencing of therapy for patients with diffuse large B‐cell lymphoma in the era of novel drugs
Karsten, I. E., Shumilov, E., Schmitz, N., & Lenz, G. (2024) · British Journal of Haematology · doi:10.1111/bjh.19860 · Cited by 26
Ahmed, N., Kambhampati, S., Hamadani, M., Hu, Z., Grover, N. S., Shadman, M. S., Locke, F. L., Gerson, J. N., Frank, M. J., Budde, L. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015014 · Cited by 25
How I treat older patients with relapsed/refractory diffuse large B-cell lymphoma
Wallace, D. S., Loh, K. P., & Casulo, C. (2024) · Blood · doi:10.1182/blood.2024024788 · Cited by 24
Bharadwaj, S., Lau, E., Hamilton, M. P., Goyal, A., Srinagesh, H. K., Jensen, A. M., Lee, D. C., Mallampet, J., Elkordy, S., Syal, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008975 · Cited by 22
Kambhampati, S., Merryman, R. W., Wang, Y., Gaulin, C., Bezerra, E. D., Voorhees, T. J., Seshadri, M. R., Falade, A. S., Habib, A., Ayers, A. A., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27548 · Cited by 19
Dreger, P., Corradini, P., Gribben, J. G., Glaß, B., Jerkeman, M., Kersten, M. J., Morschhauser, F., Mussetti, A., Viardot, A., Zinzani, P. L., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(23)00307-1 · Cited by 18
Valtis, Y. K., Devlin, S. M., Shouval, R., Rejeski, K., Corona, M., Luna, A., Rivas‐Delgado, A., Luttwak, E., Cassanello, G., Landego, I., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014555 · Cited by 18
Self-citationAdvancing CAR-T cell therapy: Insights into patient biology, leukapheresis, and cryopreservation
Blanco, B., Mfarrej, B. G., LU, H., Irwin, L., Salmon, J., Morris, D., & Bowden, R. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.045 · Cited by 15
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 15
Shadman, M. S., Ahmed, S., Byrne, M. T., Chávez, J. C., Kamdar, M. K., Sorror, M. L., Perales, M., Hill, J. A., Moslehi, J. J., & Miklos, D. B. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.10.025 · Cited by 15
Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment
Pelzl, R. J., Benintende, G., Gsottberger, F., Scholz, J. K., Ruebner, M., Yao, H., Wendland, K., Rejeski, K., Altmann, H., Petkovic, S., et al. (2025) · Blood · doi:10.1182/blood.2024027877 · Cited by 14
Self-citationA paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma
Brooks, T., & Caimi, P. F. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101140 · Cited by 14
Tun, A. M., Patel, R. D., St‐Pierre, F., Ouchveridze, E., Niu, A., Thordardottir, T. H., Obasi, J., Rosenthal, A. C., Pophali, P. A., Fenske, T. S., et al. (2024) · American Journal of Hematology · doi:10.1002/ajh.27381 · Cited by 13
Grégoire, C., de Oliveira, B. C., Caimi, P. F., Caers, J., & Melenhorst, J. J. (2024) · British Journal of Haematology · doi:10.1111/bjh.19751 · Cited by 13
Chaganti, S., Fox, C. P., Maybury, B. D., Burton, C., Barrington, S. F., Illidge, T., Kalakonda, N., Eyre, T. A., McKay, P., Kühnl, A., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20129 · Cited by 13
Iacoboni, G., Sánchez-Salinas, M. A., Rejeski, K., Martín‐López, A. Á., Kwon, M., Navarro, V., Jalowiec, K. A., Hernani, R., Reguera, J. L., Gallur, L., et al. (2024) · HemaSphere · doi:10.1002/hem3.86 · Cited by 13
Self-citationBISPECIFIC ANTIBODIES AND CART IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING
Puppi, M., Sacchetti, I., Mancuso, K., Tacchetti, P., Pantani, L., Rizzello, I., Iezza, M., Talarico, M., Manzato, E., Masci, S., et al. (2025) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2025.045 · Cited by 12
Casulo, C., & Sehn, L. H. (2025) · Blood · doi:10.1182/blood.2024026018 · Cited by 12
Are we there yet? The road to faster and more efficient CAR T cell manufacturing
Matos, L. N., Costa, M. S., Serra, M., & Costa, M. H. G. (2026) · Journal of Biological Engineering · doi:10.1186/s13036-026-00666-5 · Cited by 12
CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges
Shune, L. O., Frigault, M. J., & Riedell, P. A. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009793 · Cited by 11
Iacoboni, G., Kyvsgaard, E. R., Navarro, V., Russler‐Germain, D. A., Lewis, K. L., Martín, A., Carro, I., Thompson, P. A., Therwhanger, D., Quintela, D., et al. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018546 · Cited by 10
Self-citationBiomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma
Gong, I. Y., Tran, D., Saibil, S. D., Laister, R. C., & Kuruvilla, J. G. (2024) · HemaSphere · doi:10.1002/hem3.130 · Cited by 10
Building the future management of follicular lymphoma with T-cell–redirecting strategies
Iacoboni, G., & Morschhauser, F. (2024) · Blood · doi:10.1182/blood.2024025699 · Cited by 10
Self-citationJo, T., Yoshihara, K., Ri, M., Tsukada, N., Mimura, N., Fujii, K., Fukushima, K., Fujiwara, S., Shimura, Y., Haraguchi, K., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100051 · Cited by 9
Dreger, P., Ahmed, S., Bazarbachi, A. A., Dietrich, S., Fenske, T. S., Ghosh, N., Hermine, O., & Hamadani, M. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02599-x · Cited by 9
Bastos‐Oreiro, M., Gutierrez, A. M., Cabero, A., López‐Jiménez, J., Villafuerte, P., Ubieto, A. J., de Oña, R., de la Fuente, A., Navarro, B., Peñalver, J., et al. (2024) · Cancers · doi:10.3390/cancers16071285 · Cited by 9
The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy
Jacobs, R., & Jacobson, C. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1384600 · Cited by 9
Current treatment approach and future perspectives in B cell lymphoma
Yamauchi, N., & Maruyama, D. (2024) · International Journal of Hematology · doi:10.1007/s12185-024-03879-w · Cited by 9
Large B-cell lymphoma: The LYSA pragmatic guidelines
Sesques, P., Manson, G., Dubois, S., Gros, F., Brisou, G., Sarkozy, C., Bernard, S., Bourbon, E., Fornecker, L., Durot, É., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116070 · Cited by 8
Makni‐Maalej, K., Alotaibi, S., Fernandes, Q., Ahmed, S. O., Mestiri, S., Bougarn, S., Amir, W., Syed, F., Kharfan‐Dabaja, M. A., Merhi, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1762453 · Cited by 7
Pleitez, H. J. G., Saowapa, S., Maldonado, A., Kanitthamniyom, C., Bernal, D. A. O., & Tijani, L. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70025 · Cited by 7
Progress in the diagnosis and treatment of diffuse large B-cell lymphoma — State of the art
Czyż, A. (2025) · Acta Haematologica Polonica · doi:10.5603/ahp.108476 · Cited by 7
Fowler, N. H., Chávez, J. C., & Riedell, P. A. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01070-z · Cited by 7
Donzelli, L., Antonacci, M., Zhdanovskaya, N., Petrucci, L., Palma, M. D., Martelli, M. P., & Rocco, A. D. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05962-y · Cited by 6
Chen, L., Pan, Y., Zhang, H., Chen, Y., Wang, C., Qiu, Z., Lu, H., & Chen, L. (2025) · Nature Communications · doi:10.1038/s41467-025-56509-2 · Cited by 6
The future of follicular lymphoma management: strategies on the horizon
Mulvey, E. C., Rutherford, S. C., & Leonard, J. P. (2025) · Blood · doi:10.1182/blood.2024026017 · Cited by 6
Boccellato, E., Comba, L., Tavarozzi, R., Castellino, C., Foglietta, M., Mattei, D. G., Ladetto, M., Massaia, M., & Castellino, A. (2025) · Cancers · doi:10.3390/cancers17132239 · Cited by 6
Vučinić, V., Tumewu, T., Brückner, M., Kirchberg, J., Jentzsch, M., Buhmann, R., Remane, Y., Hoffmann, S., Ramdohr, F., Merz, M., et al. (2025) · Transfusion · doi:10.1111/trf.18354 · Cited by 6
Peñalver, F., Magnano, L., Álvarez, S. A., Jiménez-Ubieto, A., López‐Guillermo, A., & Sancho, J. (2026) · Cancers · doi:10.3390/cancers18030395 · Cited by 6
Wu, M., Sun, P., Zhao, B., Yang, H., Xia, Y., Nie, M., Cai, Q., Huang, H., Huang, H., Xia, Z., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04041-z · Cited by 5
Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
Kumar, E. A., & Okosun, J. (2025) · Hematological Oncology · doi:10.1002/hon.70070 · Cited by 5
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma
Lue, J. K., Healton, S. E., & Salles, G. A. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.06.013 · Cited by 5
CAR T cells and T cell engagers for autoimmunity—lessons from hematology
Lindner, S., & Nagler, A. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02808-1 · Cited by 5
Martínez‐Cibrián, N., Ortiz‐Maldonado, V., Español‐Rego, M., Alserawan, L., Velázquez, S. N., Albiol, N., Lozano, M., Charry, P. A., Magnano, L., Rivero, A., et al. (2025) · HemaSphere · doi:10.1002/hem3.70166 · Cited by 4
Gupta, S., & Bachanová, V. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2560082 · Cited by 4
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Merryman, R. W., Rutherford, S. C., Ansell, S. M., Armand, P. A., Leonard, J. P., Nastoupil, L. J., Smith, S. M., Timmerman, J. M., Zelenetz, A. D., Gutierrez, M. E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025018079 · Cited by 4
Management of relapsed/refractory DLBCL in the era of novel agents and new approaches
Gong, I. Y., & Kuruvilla, J. G. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2599994 · Cited by 4
van den Broecke, L., der Vreken, A. V., Watté, F., Meeus, F., Veirman, K. D., Breckpot, K., Bruyne, E. D., & Menu, E. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02923-x · Cited by 4
Manzar, G. S., Wu, S. Y., Dudzinski, S. O., Cha, E. E., Yoder, A. K., Corrigan, K. L., Nasr, L. F., Sallard, G., Ahmed, S., Fayad, L., et al. (2024) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2024.09.023 · Cited by 4
T‐Cell Redirecting Strategies in Large B‐Cell Lymphoma and Follicular Lymphoma
Iacoboni, G. (2025) · Hematological Oncology · doi:10.1002/hon.70068 · Cited by 4
Self-citationIp, A., Pia, A. D., & Goy, A. H. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.02.010 · Cited by 4
Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas
Hu, B., Korsos, V., & Palomba, M. L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394057 · Cited by 4
Panopoulou, A., Mehra, V., Cwynarski, K., Morley-Smith, A. C., Hwang, A., O'Reilly, M. A., Roddy, H., & Roddie, C. (2025) · eJHaem · doi:10.1002/jha2.70006 · Cited by 3
Self-citationA SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
Marchetti, M., Corradini, P., Arcaini, L., Bramanti, S., Rocco, A. D., Ladetto, M., Luminari, S., Rigacci, L., & Zinzani, P. L. (2025) · Hematological Oncology · doi:10.1002/hon.70125 · Cited by 3
Dismantling relapsed/refractory mantle cell lymphoma
Ryan, C. E., & Kumar, A. A. (2024) · Blood Reviews · doi:10.1016/j.blre.2024.101221 · Cited by 3
Your chemo is no good here: management of high-risk MCL
Sawalha, Y., & Maddocks, K. J. (2024) · Hematology · doi:10.1182/hematology.2024000658 · Cited by 3
Advances in the treatment of high burden Follicular lymphoma: a Comprehensive review
Luttwak, E., Kumar, A. J., & Salles, G. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2447371 · Cited by 3
Farooqi, H. A., Ullah, M. S., Raza, A., Sadiq, Z., Shaikh, W. A., Muhammad, R., & Hussain, M. S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104611 · Cited by 3
Current landscape of frontline and relapsed follicular lymphoma trials
Ng, L. C. K., & Casulo, C. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100131 · Cited by 3
Jo, T., Arai, Y., Shimizu, T., Kitawaki, T., Sakamoto, T., Mizumoto, C., Kanda, J., Nishikori, M., Yamashita, K., Nagao, M., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20266 · Cited by 3
Infectious Complications Following CD30 Chimeric Antigen Receptor T-cell Therapy in Adults
Cao, F., Xiu, Y., Mohnasky, M., Serody, J. S., Armistead, P. M., Dotti, G., Smith, M. M., Huggins, J., Messina, J. A., Ramachandran, B., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf541 · Cited by 3
Kubo, R., Onodera, K., Onishi, Y., Fukuhara, N., & Harigae, H. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06150-8 · Cited by 3
Tatake, I. J., & Arnason, J. E. (2024) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101601 · Cited by 3
Farina, M., & Re, A. (2025) · Recenti Progressi in Medicina · doi:10.1701/4460.44568 · Cited by 3
Zhang, Y., Ren, Y., Zhuang, J., Yuan, L., Wang, Z., Zhang, X., Wang, W., Cheng, Z., Cheng, L., Li, J., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71162 · Cited by 2
Diffuse large B-cell lymphoma: what clinical progress have we seen in the last 5 years?
Nolan, J., & Kuruvilla, J. G. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2587276 · Cited by 2
Selecting the best treatment approach and optimizing sequencing strategies in large B-cell lymphoma
Iacoboni, G., & Morschhauser, F. (2025) · Hematology · doi:10.1182/hematology.2025000740 · Cited by 2
Self-citationIkoma, Y., Nakamura, N., Kitagawa, J., Hayase, N., Takada, E., Matsumoto, T., Shibata, Y., Nakamura, H., Fujita, K., Lee, S., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70164 · Cited by 2
Yagi, Y., Kanemasa, Y., Goto, H., Yamamoto, M., Miyao, K., Hagihara, M., Kitawaki, T., Shimoyama, T., Hanajiri, R., Makita, S., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-02802-7 · Cited by 2
Redesigning CAR therapy to tackle immune effector cell-associated hematotoxicity
Kooniyil, M. S., Alex, P. T., Muthuvel, M., Srivastava, A., & Martin, S. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06982-6 · Cited by 2
CAR-NK cell therapy for hematological malignancies
Manzar, G. S., Hasan, M. F., Moore, M., Tiberti, S., Başar, R., & Daher, M. (2026) · Blood Advances · doi:10.1182/bloodadvances.2024014082 · Cited by 2
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
Xing, R., Yang, A., Huang, J., Wang, L., Guo, W., Cui, Q., Tang, X., Ma, Y., Hu, K., He, T., et al. (2026) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-26-0128 · Cited by 2
Šýkorová, A., Folber, F., Polgárová, K., Móciková, H., Ďuraš, J., Steinerová, K., Obr, A., Heindorfer, A., Ladická, M., Lukáčová, Ľ., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70138 · Cited by 2
Pérez‐Lamas, L., Sandoval-Sus, J. D., & Chávez, J. C. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2451888 · Cited by 2
Chan, T., Champagne, J., & Boudreault, J. (2024) · Cureus · doi:10.7759/cureus.66124 · Cited by 2
The emerging role of melflufen and peptide-conjugates in multiple myeloma
Moukalled, N. M., Dalle, I. A., Cheikh, J. E., Ye, Y., Malarad, F., Mohty, M., & Bazarbachi, A. A. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001090 · Cited by 2
Sergeev, V. S., Emelyanova, N., Витальевич, М. В., Николаевич, Г. И., Lepik, K. V., Shakirova, A. I., Нехаева, Т. Л., Балдуева, И. А., Zyuzgin, I., Popova, M. O., et al. (2023) · Cellular Therapy and Transplantation · doi:10.18620/ctt-1866-8836-2023-12-4-50-57 · Cited by 2
Fujioka, E., Kiyasu, J., Choi, I., Yagi, Y., Sawabe, T., Oyama, M., Hoashi, K., Tsuda, M., Takamatsu, A., Haji, S., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5175-24 · Cited by 1
Metadata
- Authors
- Iacoboni, G., Navarro, V., Martín-López, A. Á., Rejeski, K., Kwon, M., Jalowiec, K. A., Amat, P., Reguera-Ortega, J. L., Gallur, L., Blumenberg, V., Gutiérrez-Herrero, S., Roddie, C., Benzaquén, A., Delgado-Serrano, J., Sánchez-Salinas, M. A., Bailén, R., Carpio, C., López-Corral, L., Hernani, R., Bastos, M., O'Reilly, M., Martín-Martín, L., Subklewe, M., & Barba, P.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Oncology Data Science (ODySey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
- LMU Klinikum (DE)
- Hospital General Universitario Gregorio Marañón (ES)
- University Hospital of Bern (CH)
- Hospital Clínico Universitario de Valencia (ES)
- Hematology Department, Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Universidad de Sevilla, Sevilla, Spain
- Universidad de Salamanca (ES)
- University College London (GB)
- Haematology Department, Hospital Clínico Universitario, Valencia, Spain
- Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Cancer Research Centre (IBMCC, USAL-CSIC), Institute for Biomedical Research of Salamanca (IBSAL) and Department of Medicine and Cytometry Service (NUCLEUS Research Support Platform), University of Salamanca (USAL), Salamanca, Spain
- ORCID
- Iacoboni, Gloria
- Navarro, Víctor
- Rejeski, Kai
- Kwon, Mi
- Jalowiec, Katarzyna Aleksandra
- Amat, Paula
- Gallur, Laura
- Blumenberg, Viktoria
- Gutiérrez-Herrero, Sara
- Roddie, Claire
- Benzaquén, Ana
- Sánchez-Salinas, Mario Andrés
- Bailén, Rebeca
- Carpio, Cecilia
- Hernani, Rafael
- Bastos, Mariana
- O'Reilly, Maeve
- Martín-Martín, Lourdes
- Subklewe, Marion
- Barba, Pere
- Venue
- Journal of Clinical Oncology
- Published
- 2024-01-10
- Volume
- 42
- Issue
- 2
- Pages
- 205-217
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4387900511
- Cited by
- 143
- References
- 44
- Citations by year
- 2026: 40 · 2025: 53 · 2024: 41
- FWCI
- 17.44
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- bendamustine, large B-cell lymphoma, relapsed/refractory lymphoma, CAR T-cell therapy, CD19 CAR T cells, apheresis, overall response rate, progression-free survival, overall survival, drug-drug interactions, platelet count
- MeSH terms
- Bendamustine Hydrochloride, Receptors, Chimeric Antigen, Blood Component Removal, Humans, Immunotherapy, Adoptive, Lymphoma, Large B-Cell, Diffuse, Antigens, CD19, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.